Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study

Lung Cancer · Published 2026-07-27 · DOI 10.1016/j.lungcan.2026.109554

Authors (11)

Xiaohuan Zhou, Yi Feng, Jie Liang, Xin Bi, Qiu Zhong, Lipeng Xue, Jieshuo Wang, Jianxing He, Liping Liu, Bo Cheng, Wenhua Liang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zhou, X., Feng, Y., Liang, J., et al. (2026). Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study. Lung Cancer. https://doi.org/10.1016/j.lungcan.2026.109554

Related articles

• Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 · MMWR Recommendations and Reports · 2023 · Cites or is cited by this article
• Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors · Journal of Immunotherapy and Precision Oncology · 2024 · Cites or is cited by this article
• Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma · Lung Cancer · 2026 · Same journal
• Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT · Lung Cancer · 2026 · Same journal
• BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer · Lung Cancer · 2026 · Same journal
• Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients · Lung Cancer · 2026 · Same journal
• Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives · Lung Cancer · 2026 · Same journal
• Time-dependent bias in local consolidative therapy for EGFR-mutant metastatic non-small cell lung cancer · Lung Cancer · 2026 · Same journal
• Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy · Lung Cancer · 2026 · Same journal
• CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer · Lung Cancer · 2026 · Same journal